Fexaramine Inhibits Receptor Activator of Nuclear Factor-κB Ligand-induced Osteoclast Formation via Nuclear Factor of Activated T Cells Signaling Pathways.
10.11005/jbm.2017.24.4.207
- Author:
Ting ZHENG
1
;
Na Young KIM
;
Mijung YIM
Author Information
1. College of Pharmacy, Sookmyung Women's University, Seoul, Korea. myim@sm.ac.kr
- Publication Type:Original Article
- Keywords:
Genes fos;
NF-kappa B;
Osteoclasts;
RANK Ligand
- MeSH:
Animals;
Arthritis, Rheumatoid;
Blotting, Western;
Bone Diseases;
Bone Resorption;
Dentin;
Down-Regulation;
Glycogen Synthase Kinases;
In Vitro Techniques;
Macrophage Colony-Stimulating Factor;
Macrophages;
Mice;
NF-kappa B;
Osteoclasts*;
Osteoporosis;
Periodontitis;
Phosphorylation;
Phosphotransferases;
RANK Ligand;
Real-Time Polymerase Chain Reaction;
RNA, Messenger;
T-Lymphocytes*
- From:Journal of Bone Metabolism
2017;24(4):207-215
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Osteoclasts are bone resorbing cells and are responsible for bone erosion in diseases as diverse as osteoporosis, periodontitis, and rheumatoid arthritis. Fexaramine has been developed as an agonist for the farnesoid X receptor (FXR). This study investigated the effects of fexaramine on receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced osteoclast formation and signaling pathways. METHODS: Osteoclasts were formed by culturing mouse bone marrow-derived macrophages (BMMs) with macrophage colony-stimulating factor (M-CSF) and RANKL. Bone resorption assays were performed using dentine slices. The mRNA expression level was analyzed by real-time polymerase chain reaction. Western blotting assays were conducted to detect the expression or activation level of proteins. Lipopolysaccharide-induced osteoclast formation was performed using a mouse calvarial model. RESULTS: Fexaramine inhibited RANKL-induced osteoclast formation, without cytotoxicity. Furthermore, fexaramine diminished the RANKL-stimulated bone resorption. Mechanistically, fexaramine blocked the RANKL-triggered p38, extracellular signal-regulated kinase, and glycogen synthase kinase 3β phosphorylation, resulting in suppressed expression of c-Fos and NF of activated T cells (NFATc1). Consistent with the in vitro anti-osteoclastogenic effect, fexaramine suppressed lipopolysaccharide-induced osteoclast formation in the calvarial model. CONCLUSIONS: The present data suggest that fexaramine has an inhibitory effect on osteoclast differentiation and function, via downregulation of NFATc1 signaling pathways. Thus, fexaramine could be useful for the treatment of bone diseases associated with excessive bone resorption.
